Bufuralol
Bufuralol has been in phase III clinical trials for the treatment of hypertension. However, this research has been discontinued.
The compound was co-developed by Roche and Helsinn.
General Information
Update Date：2016-05-26
- Drug Name：
- Bufuralol
- Research Code：
- Bufuralol; Ro-34787
- Trade Name：
- MOA：
- β-adrenoceptor antagonist
- Indication：
- Hypertension
- Status：
- Phase Ⅲ (Discontinued)
- Company：
- Roche (Originator), Helsinn (Originator)
- Sales：
- ATC Code：
Chemical Structure
Update Date：2015-11-11
|
Molecular Weight | 261.36 | ||||||||||||
| Formula | C16H23NO2 | |||||||||||||
| CAS No. | 54340-62-4 (Bufuralol); | |||||||||||||
| Chemical Name | 2-Benzofuranmethanol, a-[[(1,1-dimethylethyl)amino]methyl]-7-ethyl- | |||||||||||||
| Bufuralol （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||
Synthesis & Impurities
Update Date：2016-02-24
